170 related articles for article (PubMed ID: 35851929)
21. Management of prolactinomas in children and adolescents; which factors define the response to treatment?
Alikasifoglu A; Celik NB; Ozon ZA; Gonc EN; Kandemir N
Pituitary; 2022 Feb; 25(1):167-179. PubMed ID: 34518999
[TBL] [Abstract][Full Text] [Related]
22. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia.
Furtado SV; Saikiran NA; Ghosal N; Hegde AS
Pediatr Neurol; 2010 Jan; 42(1):72-4. PubMed ID: 20004869
[TBL] [Abstract][Full Text] [Related]
23. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
24. Ten-year follow-up of a giant prolactinoma.
Fernandes V; Santos MJ; Almeida R; Marques O
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26590188
[TBL] [Abstract][Full Text] [Related]
25. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
Arya VB; Aylwin SJB; Hulse T; Ajzensztejn M; Kalitsi J; Kalogirou N; Bodi I; Thomas N; Hampton T; Kapoor RR; Buchanan CR
Clin Endocrinol (Oxf); 2021 Mar; 94(3):413-423. PubMed ID: 33340135
[TBL] [Abstract][Full Text] [Related]
26. Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox.
Tamagno G; Daly AF; Deprez M; Vroonen L; Andris C; Martin D; Beckers A
Ann Endocrinol (Paris); 2008 Feb; 69(1):47-52. PubMed ID: 18082643
[TBL] [Abstract][Full Text] [Related]
27. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
28. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
29. Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes.
Iglesias P; Arcano K; Berrocal VR; Bernal C; Villabona C; Díez JJ
Horm Metab Res; 2018 Nov; 50(11):791-796. PubMed ID: 30396208
[TBL] [Abstract][Full Text] [Related]
30. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
[TBL] [Abstract][Full Text] [Related]
31. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
32. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
33. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
O'Sullivan SM; Farrant MT; Ogilvie CM; Gunn AJ; Milsom SR
Aust N Z J Obstet Gynaecol; 2020 Jun; 60(3):405-411. PubMed ID: 31583693
[TBL] [Abstract][Full Text] [Related]
34. A case of pediatric atypical prolactinoma: significance of a multidisciplinary treatment approach.
Inoue A; Ohnishi T; Kohno S; Kitazawa R; Mizuno Y; Nishikawa M; Ohue S
Clin Neurol Neurosurg; 2014 Sep; 124():138-41. PubMed ID: 25048518
[No Abstract] [Full Text] [Related]
35. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
36. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
37. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
38. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
39. Current indications for the surgical treatment of prolactinomas.
Smith TR; Hulou MM; Huang KT; Gokoglu A; Cote DJ; Woodmansee WW; Laws ER
J Clin Neurosci; 2015 Nov; 22(11):1785-91. PubMed ID: 26277642
[TBL] [Abstract][Full Text] [Related]
40. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
